fda glp-1 compounding enforcement october 2025 Compounded GLP-1s: What to Do If Supply Stops FDA Update: Current Guidelines for

[DOI] [PubMed] [Google Scholar] 302.Ma J., Li C., Wang J., Gu J

Side effects are typically mild and temporary, such as slight soreness at the injection site

What the results showed About 9 out of every 10,000 people in the GLP-1 group were diagnosed with ischemic optic neuropathy over 18 months

3 The report by Breitzig et al, 4 from data obtained from a commercial claims database, indicates that among privately insured persons with mood disorders, there has been an increase in the prescription of GLP-1 RAs (ie, 1.5%7.2%) during the time period 20182023, with primary care and nurse practitioners rather than psychiatrists increasing prescription volume